Relay Therapeutics Inc. (NASDAQ: RLAY) is jumping after the company reported encouraging initial data from its Phase 2 ReInspire trial of zovegalisib (RLY‑2608) in patients with rare,…
April 24, 2026
SureNano Science Launches FDA-Track Toxicology Program for GEP-44, Eyes Ibogaine IP Acquisition
SureNano Science (CSE: SURE | OTCQB: SURNF) is pushing its lead weight loss and diabetes candidate GEP-44 into a critical new phase, announcing the launch…
Alpha Tau Medical (NASDAQ: DRTS) has hit a key milestone in its pancreatic cancer program, successfully treating the first pancreatic cancer patient in Europe with its…
PharmaTher Holdings (OTCQB: PHRM) says President Trump’s April 18 executive order, could materially improve the policy environment for innovative ketamine‑based therapies. The order instructs HHS, FDA,…
The Presidential Executive order signed Saturday, directs federal health and drug agencies to accelerate research and review of psychedelic therapies for serious mental illness, with…
April 13, 2026
Allogene Stock Jumps As Off‑The‑Shelf CAR‑T Wipes Out Residual Lymphoma In Early Readout
Allogene Therapeutics (NASDAQ: ALLO) is up more than 50%, trading sharply higher after early data showed its off‑the‑shelf CAR‑T candidate cema‑cel eliminated lingering lymphoma cells far…
April 02, 2026
BioCardia Seeks Accelerated FDA Path for CardiAMP Cell Therapy in Ischemic Heart Failure
BioCardia, Inc. (NASDAQ: BCDA) has submitted full CardiAMP Heart Failure clinical data to the U.S. Food and Drug Administration and requested a meeting this quarter…
March 27, 2026
AstraZeneca’s IL‑33 Drug Delivers Big COPD Win
AstraZeneca’s (NYSE: AZN) tozorakimab just delivered Phase III COPD data that can move the needle on a major respiratory asset, showing clinically meaningful exacerbation reductions…
Kymera Therapeutics, Inc. (NASDAQ: KYMR) presented new clinical data for KT-621, its investigational oral therapy for inflammatory diseases, during the American Academy of Dermatology (AAD)…
Shares of Intellia Therapeutics (NASDAQ: NTLA) moved higher after the U.S. Food and Drug Administration lifted a clinical hold on the company’s Phase 3 gene-editing…
Eikon Therapeutics priced an upsized initial public offering, raising $381 million in new capital as it transitions from heavily venture-backed startup to publicly traded biotech….
Prelude Therapeutics (NASDAQ:PRLD) received a regulatory green light after the U.S. Food and Drug Administration cleared an early-stage clinical study for its blood cancer candidate…